CN111925296A - 一种盐酸甲氧明的单晶及其制备方法 - Google Patents
一种盐酸甲氧明的单晶及其制备方法 Download PDFInfo
- Publication number
- CN111925296A CN111925296A CN202010810011.1A CN202010810011A CN111925296A CN 111925296 A CN111925296 A CN 111925296A CN 202010810011 A CN202010810011 A CN 202010810011A CN 111925296 A CN111925296 A CN 111925296A
- Authority
- CN
- China
- Prior art keywords
- single crystal
- threo
- methoxamine hydrochloride
- erythro
- methoxamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004269 methoxamine hydrochloride Drugs 0.000 title claims abstract description 148
- 239000013078 crystal Substances 0.000 title claims abstract description 139
- YGRFXPCHZBRUKP-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(C(O)C(C)N)=C1 YGRFXPCHZBRUKP-UHFFFAOYSA-N 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title abstract description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- GIZSHQYTTBQKOQ-UHFFFAOYSA-N threo-Syringoylglycerol Chemical compound COC1=CC(C(O)C(O)CO)=CC(OC)=C1O GIZSHQYTTBQKOQ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 12
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 10
- 238000001225 nuclear magnetic resonance method Methods 0.000 abstract description 10
- 238000003908 quality control method Methods 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 7
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 15
- 229960005192 methoxamine Drugs 0.000 description 15
- 238000007789 sealing Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种盐酸甲氧明的单晶及其制备方法,分别为赤式盐酸甲氧明单晶和苏式盐酸甲氧明单晶,赤式盐酸甲氧明单晶由两分子赤式盐酸甲氧明组成,组成赤式盐酸甲氧明单晶的两分子赤式盐酸甲氧明互为对映异构体;苏式盐酸甲氧明单晶由两分子苏式盐酸甲氧明组成,组成苏式盐酸甲氧明单晶的两分子苏式盐酸甲氧明互为对映异构体。本发明的赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶在单晶的晶体参数上存在显著的差异,能够清楚的将赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶区别开来,为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
Description
技术领域
本发明涉及药物领域,具体涉及一种盐酸甲氧明的单晶及其制备方法。
背景技术
盐酸甲氧明有2个手性碳,根据取代基团氨基和羟基是否分布在手性碳原子同侧可分为苏式和赤式,苏式盐酸甲氧明活性仅为赤式盐酸甲氧明的1/10,且有抑制食欲的不良反应,故应生产工艺中加以控制。但是现有的结构确证过程中采用普通的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明,给质量控制造成了困难。
发明内容
本发明的目的在于克服现有技术存在的不足之处而提供一种盐酸甲氧明的单晶及其制备方法。
为实现上述目的,本发明采取的技术方案为:一种赤式盐酸甲氧明单晶,所述赤式盐酸甲氧明单晶由两分子赤式盐酸甲氧明组成,所述赤式盐酸甲氧明的结构式如式Ⅰ或者式Ⅱ所示;所述组成赤式盐酸甲氧明单晶的两分子赤式盐酸甲氧明互为对映异构体;
发明人通过研究成功制备了一种由两分子赤式盐酸甲氧明组成的赤式盐酸甲氧明单晶,同时发明人也成功制备了一种由两分子苏式盐酸甲氧明组成的苏式盐酸甲氧明单晶,发明人通过晶体参数表征,发现赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶在单晶的晶体参数上存在显著的差异,能够清楚的将赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶区别开来,而且上述的赤式盐酸甲氧明单晶参数稳定,可以作为表征赤式盐酸甲氧明的依据,发明人制备的赤式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
优选地,所述组成赤式盐酸甲氧明单晶的其中一分子的晶体骨架结构如式Ⅴ所示;
上述的赤式盐酸甲氧明单晶在晶体参数上与苏式盐酸甲氧明单晶具有显著差别,上述的赤式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
上述的赤式盐酸甲氧明单晶的晶体参数稳定,可以作为表征赤式盐酸甲氧明的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
优选地,所述赤式盐酸甲氧明单晶的单胞结构如图3所示。
本发明还提供一种上述任一所述赤式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:
将赤式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3天以上至溶剂挥发,得到所述赤式盐酸甲氧明单晶,所述有机溶剂为甲醇、乙醇、丙酮、丁酮中的一种或几种。
上述方法成功制备了一种由两分子赤式盐酸甲氧明组成的赤式盐酸甲氧明单晶,晶体参数稳定,可以作为表征赤式盐酸甲氧明的依据,而且上述制备方法简单,无需严苛的限制条件。
优选地,将赤式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3~7天至溶剂挥发。
优选地,所述有机溶剂与所述赤式盐酸甲氧明的重量比为10~100:1。
本发明还提供一种苏式盐酸甲氧明单晶,所述苏式盐酸甲氧明单晶由两分子苏式盐酸甲氧明组成,所述苏式盐酸甲氧明的结构式如式Ⅲ或者式Ⅳ所示;所述组成苏式盐酸甲氧明单晶的两分子苏式盐酸甲氧明互为对映异构体;
发明人通过研究成功制备了一种由两分子苏式盐酸甲氧明组成的苏式盐酸甲氧明单晶,同时发明人也成功制备了一种由两分子赤式盐酸甲氧明组成的赤式盐酸甲氧明单晶,发明人通过晶体参数表征,发现苏式盐酸甲氧明单晶与赤式盐酸甲氧明单晶在单晶的晶体参数上存在显著的差异,能够清楚的将赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶区别开来,而且上述的苏式盐酸甲氧明单晶参数稳定,可以作为表征苏式盐酸甲氧明的依据,发明人制备的苏式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
优选地,所述组成苏式盐酸甲氧明单晶的其中一分子的晶体骨架结构如式Ⅵ所示;
上述的苏式盐酸甲氧明单晶在晶体参数上与赤式盐酸甲氧明单晶具有显著差别,上述的苏式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
上述的苏式盐酸甲氧明单晶的晶体参数稳定,上述的苏式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
优选地,所述苏式盐酸甲氧明单晶的单胞结构如图6所示。
本发明还提供一种上述任一所述苏式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:
将苏式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3天以上至溶剂挥发,得到所述苏式盐酸甲氧明单晶,所述有机溶剂为甲醇、乙醇、丙酮、丁酮中的一种或几种。
优选地,所述有机溶剂与所述苏式盐酸甲氧明的重量比为10~100:1。
优选地,将苏式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3~7天至溶剂挥发。
本发明的有益效果在于:本发明提供了一种盐酸甲氧明的单晶及其制备方法,本发明的赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶在单晶的晶体参数上存在显著的差异,能够清楚的将赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶区别开来,而且本发明的赤式盐酸甲氧明单晶参数稳定,可以作为表征赤式盐酸甲氧明的依据,本发明的苏式盐酸甲氧明单晶参数稳定,可以作为表征苏式盐酸甲氧明的依据,本发明的赤式盐酸甲氧明单晶和苏式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
附图说明
图1为本发明实施例的赤式盐酸甲氧明的化学结构图。
图2为本发明实施例的赤式盐酸甲氧明单晶的其中一分子的晶体骨架结构示意图。
图3为本发明实施例的赤式盐酸甲氧明单晶的晶胞示意图。
图4为本发明实施例的苏式盐酸甲氧明的化学结构图。
图5为本发明实施例的苏式盐酸甲氧明单晶的其中一分子的晶体骨架结构示意图。
图6为本发明实施例的苏式盐酸甲氧明单晶的晶胞示意图。
具体实施方式
为更好的说明本发明的目的、技术方案和优点,下面将结合具体实施例对本发明作进一步说明。
实施例1
作为本发明实施例的一种赤式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:往25ml试管中加入50mg赤式盐酸甲氧明,加入3ml甲醇溶解,滤去不溶物,用封口膜封口,室温下缓慢蒸发3~7天至析出块状单晶。
实施例2
作为本发明实施例的一种赤式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:往25ml试管中加入50mg赤式盐酸甲氧明,加入4ml丙酮溶解,滤去不溶物,用封口膜封口,室温下缓慢蒸发3~7天至析出块状单晶。
对本实施例1和实施例2得到的单晶进行晶体参数表征,结果均如表1-表4所示。由表1至表4可知,赤式盐酸甲氧明单晶由两分子的赤式盐酸甲氧明组成,组成赤式盐酸甲氧明单晶的两分子赤式盐酸甲氧明互为对映异构体,根据表1-表4的晶体参数模拟单晶结构如图3所示。
表1赤式盐酸甲氧明单晶晶体参数
表4尖角参数[deg]
实施例3
作为本发明实施例的一种苏式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:往25ml试管中加入50mg苏式盐酸甲氧明,加入0.3ml乙醇和1.5ml丙酮溶解,滤去不溶物,用封口膜封口,室温缓慢蒸发3~7天,析出块状单晶。
实施例4
作为本发明实施例的一种苏式盐酸甲氧明单晶的制备方法,所述方法包括以下步骤:往25ml试管中加入50mg苏式盐酸甲氧明,加入1ml乙醇溶解,滤去不溶物,用封口膜封口,室温缓慢蒸发3~7天,析出块状单晶。
对本实施例3和实施例4得到的单晶进行晶体参数表征,结果均如表5-表8所示。由表5至表8可知,苏式盐酸甲氧明单晶由两分子的苏式盐酸甲氧明组成,组成苏式盐酸甲氧明单晶的两分子苏式盐酸甲氧明互为对映异构体,根据表5-表8的晶体参数模拟单晶结构如图6所示。
表5苏式盐酸甲氧明单晶晶体参数
表8尖角参数[deg]
实施例1-2成功制备出了赤式盐酸甲氧明单晶,实施例3-4成功制备出了苏式盐酸甲氧明单晶,发明人通过晶体参数表征,发现赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶在单晶的晶体参数上存在显著的差异,能够清楚的将赤式盐酸甲氧明单晶与苏式盐酸甲氧明单晶区别开来,而且实施例1-2的赤式盐酸甲氧明单晶参数稳定,可以作为表征赤式盐酸甲氧明的依据,实施例3-4的苏式盐酸甲氧明单晶参数稳定,可以作为表征苏式盐酸甲氧明的依据,赤式盐酸甲氧明单晶和苏式盐酸甲氧明单晶为质控检测区分赤式盐酸甲氧明和苏式盐酸甲氧明提供了一种新的依据,克服了现有的核磁共振方法难以区分赤式盐酸甲氧明和苏式盐酸甲氧明的缺陷。
最后所应当说明的是,以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照较佳实施例对本发明作了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的实质和范围。
Claims (10)
4.根据权利要求1所述的赤式盐酸甲氧明单晶,其特征在于,所述赤式盐酸甲氧明单晶的单胞结构如图3所示。
5.如权利要求1-4任一所述赤式盐酸甲氧明单晶的制备方法,其特征在于,所述方法包括以下步骤:
将赤式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3天以上至溶剂挥发,析出所述赤式盐酸甲氧明单晶,所述有机溶剂为甲醇、乙醇、丙酮、丁酮中的一种或几种。
9.根据权利要求6所述的苏式盐酸甲氧明单晶,其特征在于,所述苏式盐酸甲氧明单晶的单胞结构如图6所示。
10.一种如权要求6-9任一所述苏式盐酸甲氧明单晶的制备方法,其特征在于,所述方法包括以下步骤:
将苏式盐酸甲氧明溶解在醇类或者酮类有机溶剂中,静置3天以上至溶剂挥发,析出所述苏式盐酸甲氧明单晶,所述有机溶剂为甲醇、乙醇、丙酮、丁酮中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810011.1A CN111925296A (zh) | 2020-08-12 | 2020-08-12 | 一种盐酸甲氧明的单晶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810011.1A CN111925296A (zh) | 2020-08-12 | 2020-08-12 | 一种盐酸甲氧明的单晶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111925296A true CN111925296A (zh) | 2020-11-13 |
Family
ID=73310909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010810011.1A Pending CN111925296A (zh) | 2020-08-12 | 2020-08-12 | 一种盐酸甲氧明的单晶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111925296A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535324A (zh) * | 2023-07-07 | 2023-08-04 | 广东嘉博制药有限公司 | 一种苏式构型盐酸甲氧明的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224246A (en) * | 1978-06-12 | 1980-09-23 | International Minerals And Chemical Corporation | Process for the synthesis and separation of the threo and erythro isomers of 2-amino-1-phenyl-1-propanol |
CN102976961A (zh) * | 2012-12-24 | 2013-03-20 | 武汉武药制药有限公司 | 盐酸甲氧明的制备方法 |
-
2020
- 2020-08-12 CN CN202010810011.1A patent/CN111925296A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224246A (en) * | 1978-06-12 | 1980-09-23 | International Minerals And Chemical Corporation | Process for the synthesis and separation of the threo and erythro isomers of 2-amino-1-phenyl-1-propanol |
CN102976961A (zh) * | 2012-12-24 | 2013-03-20 | 武汉武药制药有限公司 | 盐酸甲氧明的制备方法 |
Non-Patent Citations (1)
Title |
---|
陈海龙等: ""赤式盐酸甲氧明结构表征研究"", 《广东化工》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116535324A (zh) * | 2023-07-07 | 2023-08-04 | 广东嘉博制药有限公司 | 一种苏式构型盐酸甲氧明的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111925296A (zh) | 一种盐酸甲氧明的单晶及其制备方法 | |
CN107312181B (zh) | 一种快速制备Cu-BTC的方法 | |
CN106008529A (zh) | 一种依鲁替尼溶剂化物及其制备方法 | |
CN102267957B (zh) | 非布司他a晶型的制备方法 | |
EP4257595A1 (en) | Method for preparing crystalline d-psicose | |
CN102531942B (zh) | 一种阿戈美拉汀ⅰ晶型的制备方法 | |
CN109180958A (zh) | 一种基于吡唑环的Zn(II)配位聚合物及其制备方法 | |
CN115537932B (zh) | 一种高镉掺杂的核壳Au16Cd16(SR)20团簇及其制备方法 | |
CN116143980A (zh) | 一种晶种法制备微米级球形共价有机框架COFs材料的方法 | |
CN114394972B (zh) | 一种低熔点三乙烯二胺晶体及其制备方法 | |
CN108727387A (zh) | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 | |
CN110256373B (zh) | 一种小粒度盐酸阿考替胺结晶的制备方法 | |
CN102887861B (zh) | 一种安贝生坦新晶型及其制备方法 | |
CN107286183A (zh) | 一种头孢克肟的精制方法 | |
CN110643048A (zh) | 一种钴镍双金属mof纳米管的制备方法 | |
CN110818816A (zh) | 一种舒更葡糖钠的精制结晶方法 | |
CN115137693A (zh) | 一种羧甲司坦口服制剂及其制备方法 | |
CN114195791A (zh) | 一种多元离子液体及其制备方法和应用 | |
CN110284181A (zh) | 地尔硫卓ab异构体的单晶制备方法 | |
CN108690801A (zh) | 一种便于放置的淋巴细胞分离管 | |
CN112079887A (zh) | 一种葛根素一水合物单晶及其制备方法和应用 | |
CN110372698A (zh) | 一种阿哌沙班杂质的合成方法 | |
CN111087295A (zh) | 一种戊二胺丁二酸对苯二甲酸共晶盐及其制备方法 | |
CN114685594A (zh) | 一种罗库溴铵起始物料(lk-7)单晶的制备方法 | |
CN110372635A (zh) | 氢溴酸沃替西汀α晶型的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201113 |